Short term swing trade | Buy NSE: THYROCARE | Indian stock trading advice on 9 Jun 2026

NOTE

Closing Price: ₹541 (as of Jun 08, 2026)
StopLoss*: Apply on the daily close. After the first target, reset the StopLoss to your buying price.
Duration^: Approximate holding period based on the active trading days (excluding market holidays). Actual holding may vary with the market conditions.
Upside Potential#: Based on median of the suggested buy range.

Thyrocare Technologies Limited is one of India’s leading diagnostic healthcare companies, providing pathology and preventive health testing services through a nationwide network of laboratories and collection centers. The company offers a wide range of diagnostic tests, health check-up packages, imaging services, and related healthcare products. Founded in 1996, Thyrocare serves patients, hospitals, and laboratories across India and is headquartered in Navi Mumbai. It is a subsidiary of Docon Technologies Private Limited.

Q4 FY26 Earnings Call Summary & Financial Highlights

Earnings Call Summary

Profits exploded this quarter: Q4 PAT surged 128% YoY to ₹48.70 crore on 20% revenue growth to ₹224 crore. Full-year profit for FY26 jumped 81% — a standout performance.
Full year was very strong: FY26 consolidated revenue grew 21% to ₹829 crore, driven by the core pathology business, better volumes, and an expanding franchise network.
Network hitting all-time highs: Active franchisees reached a record 10,800, growing the franchise business 18% YoY. The company processed 210 million tests for 19.2 million patients in FY26.
New specialties gaining traction: Genomics, NIPT, and advanced allergy testing are being scaled up as the next big growth drivers. The Jaanch segment grew 66% YoY, showing strong demand for disease-specific testing.

Financial Highlights

Metric	Q4 FY26 (Mar '26)	Q3 FY26 (Dec '25)	Q4 FY25 (Mar '25)	QoQ Change	YoY Change
Revenue from Operations	223.95	196	187.16	▲ 14.3%	▲ 19.7%
EBITDA	75.09	58	57.26	▲ 29.5%	▲ 31.1%
EBITDA Margin (OPM %)	33.50%	30%	30.60%	▲ 350 bps	▲ 290 bps
Net Profit (PAT)	48.7	28	21.7	▲ 73.9%	▲ 124.4%
EPS (₹)	3.07	1.82	1.36	▲ 68.7%	▲ 125.7%

Q4 FY26 Earnings Call Summary & Financial Highlights

Earnings Call Summary

Profits exploded this quarter: Q4 PAT surged 128% YoY to ₹48.70 crore on 20% revenue growth to ₹224 crore. Full-year profit for FY26 jumped 81% — a standout performance.
Full year was very strong: FY26 consolidated revenue grew 21% to ₹829 crore, driven by the core pathology business, better volumes, and an expanding franchise network.
Network hitting all-time highs: Active franchisees reached a record 10,800, growing the franchise business 18% YoY. The company processed 210 million tests for 19.2 million patients in FY26.
New specialties gaining traction: Genomics, NIPT, and advanced allergy testing are being scaled up as the next big growth drivers. The Jaanch segment grew 66% YoY, showing strong demand for disease-specific testing.

Financial Highlights

Metric	Q4 FY26 (Mar '26)	Q3 FY26 (Dec '25)	Q4 FY25 (Mar '25)	QoQ Change	YoY Change
Revenue from Operations	223.95	196	187.16	▲ 14.3%	▲ 19.7%
EBITDA	75.09	58	57.26	▲ 29.5%	▲ 31.1%
EBITDA Margin (OPM %)	33.50%	30%	30.60%	▲ 350 bps	▲ 290 bps
Net Profit (PAT)	48.7	28	21.7	▲ 73.9%	▲ 124.4%
EPS (₹)	3.07	1.82	1.36	▲ 68.7%	▲ 125.7%

Price Performance & Volume Analysis

Price Performance

Volume Analysis

Price Performance & Volume Analysis

Price Performance

Volume Analysis

Technical Analysis

Key Observations

The stock price has just broken above the neckline of the rounding bottom pattern.
If the price hold above this breakout level a upside move is likely in the near-term.

A reliable swing trading advisory service in India can help traders catch momentum early, before the crowd joins in.

Technical Image - Daily Timeframe

Technical Analysis

Key Observations

The stock price has just broken above the neckline of the rounding bottom pattern.
If the price hold above this breakout level a upside move is likely in the near-term.

A reliable swing trading advisory service in India can help traders catch momentum early, before the crowd joins in.

Technical Image - Daily Timeframe

Technical Indicators

Oscillators

Indicator	Value	Zone
RSI-14	75.04	Overbought
CCI-14	112.38	Overbought
ROC	13.91	Positive
MFI	73.48	Neutral
Stochastic %K	89.14	Bullish
William %R	-7.57	Overbought

Exponential Moving Averages (EMAs)

EMA	Value	Stock Position
5 EMA	541	Above
10 EMA	525	Above
20 EMA	500	Above
50 EMA	462	Above
100 EMA	440	Above
200 EMA	418	Above

Technical Indicators

Oscillators

Indicator	Value	Zone
RSI-14	75.04	Overbought
CCI-14	112.38	Overbought
ROC	13.91	Positive
MFI	73.48	Neutral
Stochastic %K	89.14	Bullish
William %R	-7.57	Overbought

Exponential Moving Averages (EMAs)

EMA	Value	Stock Position
5 EMA	541	Above
10 EMA	525	Above
20 EMA	500	Above
50 EMA	462	Above
100 EMA	440	Above
200 EMA	418	Above

Conclusion

Thyrocare Technologies Stock Price Forecast

Based on our positional trading tips in India, the Thyrocare Technologies price target will be INR 560 - INR 565 in the next 12-14 trading sessions.

Conclusion

Thyrocare Technologies Stock Price Forecast

Based on our positional trading tips in India, the Thyrocare Technologies price target will be INR 560 - INR 565 in the next 12-14 trading sessions.

MONEY MANAGEMENT AND TRADING RULES

Buy within the recommended price range. You may allow up to 1% flexibility beyond the range if needed.
No need to rush. The recommendation remains valid for up to 7 days, not just at market open.
Use a trailing stop-loss to protect and lock in profits.
Diversify your trading capital across our other recommended stocks to reduce risk.
Invest responsibly. Trade only with funds you can afford to lose and hedge positions where appropriate.

Analyst Summary

The research analysis is prepared by Arijit Banerjee, CMT, CFTe. He is a veteran trader and an active investor having in-depth knowledge in financial market research, advanced technical analysis, market cycle, algorithmic trading and portfolio management. Arijit is a Chartered Market Technician (CMT) accredited by CMT Association USA, the leading global authority of Technical Analysis and has been honoured by Certified Financial Technician (CFTe) from the International Federation of Technical Analysts, USA. SEBI, the regulatory body of Indian financial market also recognizes him as a Research Analyst (INH300006582).

The views expressed herein are based solely on information available publicly/internal data/other sources believed to be reliable, but is not necessarily all-inclusive and is not guaranteed as to accuracy. The recommendations provided herein is solely for informational purposes and are not intended to be and must not be taken alone as the basis for an investment/trading decision. Trading and investing are subject to market risk and the securities discussed and opinions expressed herein may not be suitable for all investors. To read the full disclosure, please click here.

Your Return Could be Much Better

Increase your Profitable!

10—12 swing trade advice / month
expected upside 6%—8% per trade
short term trade holding 1-2 weeks
minimum capital required ₹ 3-lakh
receive trade advice before 9:00 am
trade ideas by blackbox system, relied on statistics, technical, fundamental, macroeconomics and sentiment
Stocks only — no intraday or F&O